GlassScriptPhysician profile
Satjit Bhusri
NPI 1740421189
$10,071.00
in general payments reported to CMS, 2019-2025
30 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.32 · 2021: $5,552 · 2022: $1,266 · 2023: $1,312 · 2024: $1,180 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Education: $79.99 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,077.06 |
| Education | $79.99 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3,942.63 | 2021-2022 | |
| Medtronic, INC. | $797.35 | 2021-2023 | Linq II |
| Boston Scientific Corporation | $694.41 | 2021-2025 | Bodyguardian, Cds - Mct/Cem Monitoring, Varithena Administration Pack |
| Janssen Pharmaceuticals, INC | $453.49 | 2021-2024 | Xarelto |
| Abbott Laboratories | $368.92 | 2021-2024 | Supera, Jot Dx, Aveir |
| Pfizer INC. | $326.69 | 2021-2025 | |
| Tactile Systems Technology INC | $298.88 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Astrazeneca Pharmaceuticals LP | $298.20 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $273.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $254.36 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.32 | 2021-2024 | Jardiance |
| Biotronik INC. | $246.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $242.65 | 2022-2024 | Camzyos, Eliquis |
| Heartflow, INC. | $236.92 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $220.96 | 2023-2025 | Uptravi, Opsumit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $202.57 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $183.94 | 2022-2025 | Repatha, Repatha |
| Irhythm Technologies, INC. | $132.74 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals International, Plc | $118.44 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $99.72 | 2023-2025 | Onpattro, Amvuttra |
| Bardy Diagnostics, INC. | $88.52 | 2021-2022 | |
| Medicomp INC | $74.24 | 2022-2025 | Telepatch Cardiac Monitor |
| Idorsia Pharmaceuticals US INC | $60.40 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $42.92 | 2021 | |
| Kestra Medical Technology Services, INC. | $35.00 | 2024 | Assure Wcd |
| Baxter Healthcare | $35.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $30.13 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $24.95 | 2023 | Arcalyst |
| Vivaquant INC, Dba Rhythm Express | $22.32 | 2021 | |
| Philips North America LLC | $15.46 | 2025 | Ecc Solutions |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satjit Bhusri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.